Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous stromal vascular fraction-derived mesenchymal stem cells (Fuzhou General Hospital)
- Development stage
- Unknown
- Lead developer
- 900th Hospital of Joint Logistics Support Force of PLA
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This is an investigational autologous cell therapy being developed by Fuzhou General Hospital for kidney transplant recipients. The therapy involves the extraction of the stromal vascular fraction (SVF) from a patient's own adipose tissue, which is then cultured to isolate and expand mesenchymal stem cells (MSCs). These autologous MSCs are infused into the recipient during the kidney transplant operation and at subsequent intervals (postoperative days 7, 14, and 21). The primary therapeutic objective is to utilize the immunomodulatory properties of MSCs to reduce the incidence of acute rejection, improve allograft function, and potentially decrease the long-term requirement for standard immunosuppressive medications in living-related kidney transplant recipients.
- Other names
- SVF-MSCautologous SVF-derived MSCsautologous stromal vascular fraction-derived mesenchymal stem cells
Beyond the preview
Go deeper on autologous stromal vascular fraction-derived mesenchymal stem cells (Fuzhou General Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous stromal vascular fraction-derived mesenchymal stem cells (Fuzhou General Hospital).